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REVIEW ARTICLE
The central role of extracellular vesicles in the
mechanisms of thrombosis in paroxysmal nocturnal
haemoglobinuria: a review
Be´range`re Devalet1*, Franc¸ois Mullier2,3, Bernard Chatelain2,
Jean-Michel Dogne´3 and Christian Chatelain1
1Department of Hematology, Namur Thrombosis and Hemostasis Center (NTHC), CHU Dinant-Godinne
UCL Namur, Yvoir, Belgium; 2Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC),
CHU Dinant-Godinne UCL Namur, Yvoir, Belgium; 3Department of Pharmacy, Namur Thrombosis and
Hemostasis Center (NTHC), University of Namur, Belgium
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired disorder of the haematopoietic stem cell
that makes blood cells more sensitive to the action of complement. PNH patients experience an increased risk
of arterial and venous thrombosis  major causes of death due to this disease. Though many potential
interlaced mechanisms are suspected, extracellular vesicles (EVs) of various origins may play a central role.
The processes possibly involved are haemolysis, platelet activation, injured endothelial cells and monocyte
activation. The impact of transfusion should be evaluated. A better understanding of the mechanisms
involved may help to propose guidelines for the prophylaxis and treatment of thrombosis in PNH. In this
paper, we propose an updated review of the pathophysiology of the underlying mechanisms of thrombosis
associated with PNH, with specific focus on the prominent role of EVs.
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P
aroxysmal nocturnal haemoglobinuria (PNH) is a
rare, acquired disorder of the pluripotent haemato-
poietic stem cell and therefore can affect erythro-
cytes, leukocytes, thrombocytes (1) and probably some
endothelial cells too (2). These haematopoietic stem cells
have acquired a somatic mutation in an X-linked gene: the
phosphatidylinositol glycan class A (PIG-A). This gene is
required for the synthesis of the glycosylphosphatidylino-
sitol (GPI) anchor, which is necessary to attach some pro-
teins to the cell membrane.
The lack of synthesis of the GPI anchor leads to the
under-expression of a variety of proteins on the haemato-
poietic stem cell surface and on all cell lines that are
generated by it. By this mechanism, lack of 2 important
complement regulators is observed on the cell surface:
‘‘decay accelerating factor’’ (DAF), recognized by anti-
body CD55, and ‘‘membrane inhibitor of reactive lysis’’
(MIRL), recognized by antibody CD59. Consequently,
red blood cells are more vulnerable to the action of com-
plement, leading to complement-mediated intravascular
haemolysis (see Fig. 1) (3). As a result, a high concentra-
tion of free haemoglobin is found in the plasma, re-
sponsible for nitric oxide (NO) scavenging. NO depletion
causes smooth muscle dystonia, responsible for dysphagia
and abdominal pain. NO depletion may also contribute
to the development of arterial constriction, leading to
reduced blood flow to the kidneys (with renal failure),
arterial hypertension and pulmonary hypertension (asso-
ciated with frequent but under-diagnosed pulmonary
embolism) (4).
Management and treatment of classic PNH has been
dramatically revolutionized by the development of eculi-
zumab (Soliris† by Alexion Pharmaceuticals) and its
approval in 2007 by the US FDA and the European
Union Commission. This humanized monoclonal anti-
body blocks the activation of terminal complement C5
and prevents the formation of C5a and C5b-9, prevent-
ing haemolysis. Several beneficial effects of eculizumab
have been demonstrated, in terms of haemolysis, quality
of life (5,6), renal function (7) and life expectancy (8).

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A reduction in the incidence rate of thromboem-
bolic events (9) and a decrease in markers of thrombin
generation (10,11) were also observed during eculizumab
therapy. The mechanisms involved, however, remain
misunderstood.
Thrombosis in PNH
Clinical characteristics
Thrombotic events occur in 40% of PNH patients and
represent the major cause of death due to this disease.
Indeed, 4067% of PNH patients will die of thrombotic
complications. An initial thrombotic event increases the
relative risk of death by 5- to 10-fold (12). Understanding,
anticipating and treating thrombosis represent a major
challenge in PNH.
Thrombotic events are of venous origin in 85% of the
cases but arterial thrombosis is not so rare (15%) (4).
Thrombotic events (20.5%) involve more than 1 site at the
same time. Thrombosis not only affects usual sites such as
deep veins of the lower limbs, pulmonary arteries, cor-
onary arteries or central nervous system (CNS) arteries but
also, more typically, unusual sites such as hepatic veins
(Budd-Chiari syndrome: 40.744.0% of PNH patients
with thrombosis (12)), cavernous sinus, CNS veins, me-
senteric veins or dermal veins (13).
In PNH patients, the age of onset of thrombosis is
lower than among the general population (46 years vs.
Fig. 1. Action of complement in healthy subjects (A) and PNH patients (B). (A) Due to the presence of membrane proteins, DAF and
MIRL, a normal RBC is protected from complement activation. (B) DAF and MIRL deficiency makes the RBC sensitive to
complement attack, resulting in haemolysis. RBCred blood cells, MACmembrane attack complex.
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73 years) (4). An increased risk of thrombosis was re-
ported among African American or Latin American PNH
patients compared with other PNH patients (14). A lower
risk was reported among Chinese and Japanese PNH
patients (12). The mechanism is still unknown.
Recurrences of thrombosis despite antithrombotic
therapy (warfarin, unfractionated heparin, enoxaparin,
aspirin, tirofiban) have been described (15,16).
Thrombosis during pregnancy and post-partum seems
particularly frequent. Indeed, a maternal mortality of
20% and a perinatal mortality of 10% have been reported,
mostly due to thrombosis. Consequently, some authors
do not recommend pregnancy in patients suffering from
PNH (13).
The role of EVs
The exact pathophysiology of this hypercoagulable state
in PNH is unknown but may be multifactorial, as illus-
trated in Fig. 2. Extracellular vesicles (EVs) are sub-
micron-size cellular fragments released by eukaryotic cells
(including platelets, leukocytes, endothelial cells and red
blood cells) following activation or apoptosis. They are
highly heterogeneous both in size (301,000 nm) and in
composition. EVs are complex and ambivalent structures
that not only express both activators and inhibitors of
coagulation but also convey fibrinolytic properties. They
are therefore considered as the main regulator of the
balance between coagulation and fibrinolysis. They play a
major role in cellular cross-talk, inflammation, haemos-
tasis and thrombosis (1719).
It was demonstrated in vitro that platelet EVs have
from 50 to 100-times higher pro-coagulant activity than
platelets (20). Indeed, an inherited defect of lipid scram-
blase is seen in Scott’s syndrome, a rare autosomal reces-
sive disease. This leads to reduced production of EVs,
causing severe bleeding (2123).
EVs are known to expose phosphatidylserine on
their surface, providing a support for the assembly of
the pro-coagulant enzyme complexes  prothrombinase
and tenase (21,22,24).
Tissue factor, the principal initiator of coagulation, is
also exposed on the surface of some EVs. More and more
evidences suggest that EVs are the main carriers of cir-
culating tissue factor (TF) and, thereby, may contribute
to normal coagulation (25). However, TF activity of EVs
from non-stimulated blood was not detectable in most
studies (26). Monocytes are thought to be the only blood
cells that synthesize TF in vivo. TF is constitutively
expressed in an encrypted form in monocytes but may
be decrypted during cell activation. Indeed, monocyte’s
TF mRNA levels are increased after stimulation (26).
Some authors speculate that TF expressed on cholesterol-
rich lipid rafts on monocyte-derived EVs may take part
in the link between hypercholesterolemia and thrombosis
(27). The role of EV-associated TF in haemostasis is
not extensively discussed here because it has been well
covered in other reviews (24,28,29) and is still under
study. The synergies of phosphatidylserine and protein
disulphide isomerase as well as the recycling by endothe-
lial cells have been recently demonstrated as important
Fig. 2. Overview of the multiple mechanisms involved in the occurrence of thrombosis in PNH patients. Complement (C) activation
is responsible of haemolysis, platelet activation, endothelium injury and activation, and white blood cell (WBC) recruitment
and activation. From there, multiple mechanisms induce a hypercoagulable state with the occurrence of thrombosis. Note the central
role of extracellular vesicles (or microvesicles: MVs). ADPadenosine diphosphate, Hbhaemoglobin, NOnitric oxide, TFtissue
factor.
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in tissue factor activation (30,31). In addition, contrary
to what was believed before, very small TF-bearing EVs
(B100 nm) may have a pro-coagulant effect, especially in
the presence of phospholipids (32,33).
In PNH, complement activation at the cell surface
of GPI-deficient cells may stimulate the release of pro-
coagulant EVs. Indeed, increased levels of circulating
EVs have been measured in PNH patients, a majority of
them coming from platelets. Yet, no correlation between
the clone size and the number of EVs could be demon-
strated (34). One study (35) showed increased plasmatic
levels of TF antigen (measured by ELISA, after adjunc-
tion of triton) in 2 PNH patients suffering from recurrent
thrombotic complications, compared to normal controls.
The role of platelet activation
Platelet membranes of PNH patients are deficient in
DAF (CD55) and MIRL (CD59). It is known that com-
plement does not directly destroy platelets but is able to
induce platelet activation. Therefore, complement may
induce platelet activation and vesiculation in an insuffi-
ciently regulated manner in PNH patients. Indeed, it has
been found that PNH platelets, after membrane attack
complex (MAC) stimulation, expose more activated factor
five-binding sites and increase thrombin generation more
than that of normal platelets (36). One study also showed
increased adherence of platelets to the abdominal vessels
in PNH. This interesting feature could partly explain
the particular occurrence of mesenteric vein thrombosis in
these patients and suggest a peculiar mechanism involving
the special distribution of a hypercoagulable state in these
patients (4). In contrast, other studies showed impaired
function of PNH platelets as a result of a reactive down-
regulation in response to their chronic hyperstimulation
(36).
The number of platelet extracellular vesicles (PEVs)
is sometimes used as a marker of platelet activation (37)
and may be of particular interest in PNH. Nowadays, it
is still very difficult to find a reliable plasma marker of
platelet activation. P-selectin, b-thromboglobulin, plate-
let factor 4 (PF4) and thromboxane B2 have been studied
in physiological and pathological states but all these
have limitations (38,39). The ideal candidate should be
a specific marker of platelet, resistant to the artefacts
of venipuncture and collection and not influenced by
antithrombotic drugs. It should be measured according
to a cheap, simple and reproducible operating procedure
(38). Further research needs to be done in this field.
The controversial impact of haemolysis
Haemolysis has long been considered as a major con-
tributor of thrombosis, but its role is now controversial.
NO depletion can cause arterial constriction and thus play
a role in arterial thrombosis, but veins do not have smooth
muscle. Platelet activation may be increased by the lack
of NO (4) and by the release of adenosine diphosphate
(ADP) (40) in case of haemolysis. The impact of NO
depletion in an increase of TF expression is controver-
sial. However, no link can be made between severity of
haemolysis and thrombosis or severity of anaemia and
thrombosis (4). One study showed that human red
blood cell stroma is capable of activating the alternate
complement pathway in vitro. The ensuing interaction of
activated complement components with platelets may
lead to activation of the coagulation system (41).
Similar levels of red blood cellsderived EVs (REVs)
were found in PNH patients or healthy controls, but
in vitro experiments showed that PNH erythrocytes release
higher amounts of pro-coagulant EVs upon complement
stimulation (42). This may suggest a rapid clearance of
erythrocyte EVs from the circulation (36). We know that
vesicles are partly cleared by a scavenging receptor on the
monocytes, which can induce monocyte TF expression,
promoting coagulation. In turn, monocytes, after comple-
ment damage, can release EVs that contain TF. These EVs
may be captured by endothelial cells, increasing their own
TF expression (4,31).
Injured endothelial cells
Endothelial EV levels are also increased in PNH patients,
showing a pro-inflammatory and pro-thrombotic pheno-
type (43). The endothelial cells probably play an impor-
tant role in the pathophysiology of thrombosis in PNH.
Endothelial cells suffer from direct toxicity of free
haemoglobin released (44) but may also be particularly
sensitive to the action of complement. It has been shown
that endothelial precursor cells may be bone marrow
derived cells (2). They would then be deficient in GPI-
anchored proteins, making them more susceptible to
complement injury. This would be of particular impor-
tance for the development of thrombosis in unusual sites
(4). Increased levels of endothelial cell activation markers,
such as von Willebrand factor (VWF) or soluble vascular
cell adhesion molecule-1 (sVCAM-1), are observed in
PNH (11).
The effect of complement on other cell lines
Complement injury to other cell lines can also contribute
to thrombosis in PNH. Complement protein C5a binds to
a receptor on granulocytes and enhances recruitment and
activation of granulocytes and monocytes. This molecule
is considered as a possible link between inflammation
and thrombosis (45). In GPI-deficient white blood cells,
this mechanism may be intensified and may lead to an
important release of inflammatory molecules and EVs.
This inflammatory process induces damages to the en-
dothelium and enhances TF expression, which initiates the
coagulation cascade (4). It seems clear that complement
and coagulation systems are closely intertwined. This
has been reinforced by the fact that thrombin by itself
is able to initiate the alternative pathway of complement
(46).
Be´range`re Devalet et al.
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Tissue factor pathway inhibitor deficiency
Tissue factor pathway inhibitor (TFPI) normally limits
coagulation initiation by inhibiting TF formation. It is
mainly produced by the endothelium of the microvascu-
lature and is bound to a GPI-anchored protein. There-
fore, it lacks in PNH. In previous studies, loss of TFPI
expression has been associated with an increased risk
of thrombosis (4). In addition, a decrease of TFPI ex-
pression on circulating EVs has been observed in certain
clinical situations and may induce thrombin generation
due to unopposed TF activity (47). This could play a role
in thrombosis in PNH.
Lack of other GPI-anchored proteins
As we have already discussed, the lack of several GPI-
anchored proteins at the cell surface may lead to altered
coagulation. The GPI-anchors’ deficit may also interfere
with coagulation in an indirect manner. For example,
neutrophil proteinase-3 (PR-3) is a membrane-bound
protein, which is co-localized with GPI-anchored neu-
trophil antigen 2a. The lack of neutrophil antigen 2a
in PNH leads to loss of expression of PR-3. However,
PAR-1, the predominant human platelet thrombin re-
ceptor, is a substrate for PR-3. It has been shown that
impaired down-regulation of PAR-1 leads to an increased
propensity for platelet activation. PR-3 also modulates
coagulation in various other ways (48).
Congenital and acquired thrombophilia
Frequency of congenital thrombophilia factors (Factor
V Leiden, antithrombin deficiency, protein C or S defi-
ciency, prothrombin mutations, hyperhomocysteinaemia
and methylenetetrahydrofolate reductase mutations) is
not increased in PNH. Testing for such factors may
identify PNH patients at additional thrombotic risk, but
its value for treatment decision in PNH is still unknown
(36). A higher rate of antiphospholipid antibodies was
found in PNH patients than in healthy volunteers (49).
This could be a contributory factor for thrombosis in
PNH.
In addition, Gru¨newald et al. (50) have studied various
markers of coagulation in PNH and noted a significant
increase in pro-coagulant factor activities (factor V,
fibrinogen, factor VIII, factor IX, factor X and VWF),
with a positive correlation with clone size.
Impaired and/or increased fibrinolysis
About fibrinolysis in PNH, the results of various studies
are conflicting. The role of urokinase-type plasminogen
activator receptor (u-PAR) may however be important. U-
PAR, a GPI-linked protein expressed on neutrophils, plays
a central role in the regulation of haemostatic processes on
cell surface. Indeed, the binding of urokinase-type plas-
minogen activator (u-PA) to u-PAR converts plasminogen
into plasmin, mediating endogenous thrombolysis. This
proteolytic activity is spatially restricted to the plasma
membrane (51). In PNH, studies have shown that u-PAR
is under-expressed on the cellular surface of leukocytes
and platelets and also that concentration of soluble u-PAR
is increased in plasma of PNH patients. Furthermore,
serum-soluble u-PAR concentrations correlated with
PNH granulocyte clone size and were the highest in
patients who later developed thrombosis (52). They hy-
pothesize that u-PAR is released from PNH haematopoie-
tic cells to plasma (53). This would be the responsibility of
an impaired and displaced fibrinolytic system in PNH.
Other fibrinolytic parameters have been studied, some
of them suggesting an increased activity of the fibrinolytic
system in PNH. Indeed, elevated levels of d-dimers and of
complexes of plasmin and plasmin inhibitors were found,
as was the case for complexes of tissue-type plasminogen
activator (t-PA) and its inhibitor (PAI-1). However,
an inverse association with clone size was described and
correlations were weak (50).
In healthy subjects and in several pathological condi-
tions, it is now suspected that EVs have a fibrinolytic
activity (18). The exposure of u-PA or t-PA and their
receptor (u-PAR and annexin II) was demonstrated on
the surface of EVs from various origins (5458). Their
impact on fibrinolysis in PNH patients remains to be
studied.
The impact of transfusions
PNH patients who receive frequent transfusions of red
blood cells may have a further increased risk of throm-
bosis. Indeed, the use of transfusion was isolated as an
independent risk factor for thrombosis in PNH (15).
Unfortunately there is no prospective study that quanti-
fies the level of this risk.
An exogenous source of PEVs or REVs in PNH could
be constituted by transfusion. Indeed, patients suffer-
ing from PNH frequently need red blood cell or platelet
transfusions. Anaemia induced by haemolysis is not,
in this situation, a contraindication for red blood cell
transfusion. On the contrary, receiving allogeneic red
blood cells (in which the membrane is not GPI deficient)
is good enough to limit the stimulation of erythropoiesis,
decrease the production of deficient red blood cells and
thus lessen haemolysis and its symptoms. Red blood cell
or platelet transfusions are also required when PNH is
associated with a bone marrow failure syndrome (3). PNH
patients, receiving frequent transfusions of red blood cells,
may have a further increased risk of thrombosis. Indeed,
the use of transfusion was isolated as an independent risk
factor for thrombosis in PNH (15). However, there is
no prospective study that quantifies this risk.
Regardless of PNH, lots of observations suggest that
red blood cell transfusion is associated with increased
thrombotic events and mortality. Indeed, blood transfu-
sion in the setting of acute coronary syndromes was
associated with higher mortality (OR 3.94) (59). Khorana
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et al. (60) observed that red blood cell transfusion was
independently associated with an increased risk of venous
(OR 1.60) and arterial (OR 1.53) thrombotic events
and mortality (OR 1.34) in hospitalized cancer patients.
Similarly, Abu-Rustum et al. (61) demonstrated an asso-
ciation between transfusion and increased risk of throm-
botic events in women during adnexal or peritoneal
cancer surgery (OR 4.80), and Nilsson et al. (62) ob-
served that perioperative blood transfusion was asso-
ciated with an increased risk of venous thromboembolism
in women undergoing colorectal cancer resection (OR
1.80). More recently, an increase in perioperative graft
thrombosis was observed in patients transfused during
a surgery of lower extremity bypass (OR 2.10 to 4.80,
depending on the number of units transfused) (63).
Kumar et al. (64) also demonstrated that red blood
cell transfusion was associated with an increased risk
of thrombotic events in patients with subarachnoid
haemorrhage (OR 2.40).
The mechanisms that underlie these findings remain
unclear. It is known that red blood cell transfusions alter
viscosity by both raising haematocrit and by introducing
erythrocytes with altered viscoelastic properties into the
circulation (62). This could increase the risk of throm-
bosis. Increasing the circulating red cell mass may also
improve haemostasis (60). The depletion of NO in stored
red blood cells may promote vasoconstriction and plate-
let aggregation (59). The delivery of redox-active iron
and pro-inflammatory mediators by transfusion may also
play a role (60).
In addition, the delivery of pro-coagulant EVs con-
tained in the transfused product may be able to promote
haemostasis and increase the risk of thrombosis. Indeed,
it has been observed that the number of EVs contained in
packed red blood cells increases during storage (65) and
that red blood cellsderived EVs isolated from blood
units are capable of initiating and propagating thrombin
generation (65). Moreover, duration of red blood cell
storage was associated with increased incidence of deep
vein thrombosis in patients with traumatic injuries in a
retrospective cohort study (66).
Risk factors for thrombosis
A previous history of thrombosis and a large white blood
cell clone are well-known risk factors for thrombosis
in PNH (67). Indeed, a 10-year cumulative incidence
of thrombosis of 34.5% is observed in patients having a
large clone (50%), compared with 5.3% in patients with
a smaller clone (B50%) (40). The risk of thromboem-
bolic events increases by 1.64-fold for every 10% increase
in the size of the white blood cell clone (12). Age more
than 55 years and the use of transfusion were also
isolated as independent risk factors for a first thrombotic
event (15). Ethnicity seems to be another risk factor
for thrombosis as discussed above (14). The elevation of
D-dimers has also been associated with an increased
thrombotic risk in PNH (4).
Conclusion
Even if the management of PNH has been dramatically
revolutionized by the development of eculizumab, pre-
vention and treatment of thrombotic complications
remain a challenge.
A better understanding of the underlying pathophy-
siologic mechanisms of thrombosis in PNH should allow
us to identify new potential biomarkers of thrombosis,
such as EVs.
More and more studies have indicated a potential role
of EVs in thrombosis associated with PNH. However,
published data were produced using low-sensitive and not
standardized flow cytometry. But progress has been
performed in the field of flow cytometry (6871). There-
fore, the role of EVs should be investigated using high-
sensitive and standardized techniques. Moreover, as the
research focused on the pro-coagulant function of EVs,
its function in fibrinolysis should also be studied in the
near future.
The ultimate goal is to propose guidelines for prophy-
laxis and treatment of thrombosis associated with PNH.
Moreover, the impact of transfusion on thrombotic risk
deserves to be further studied.
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